IDEAYA Biosciences (IDYA) Net Equity Issued and Repurchased (2018 - 2025)

IDEAYA Biosciences (IDYA) has 8 years of Net Equity Issued and Repurchased data on file, last reported at $25.0 million in Q1 2025.

• For the quarter ending Q1 2025, Net Equity Issued and Repurchased fell 92.73% year-over-year to $25.0 million; the trailing twelve-month figure through Dec 2025 stood at $25.0 million (down 90.89% YoY), and the FY2025 full-year result was $25.0 million, down 90.89% from the prior year.
• Net Equity Issued and Repurchased rose to $25.0 million in Q1 2025, from -$105.6 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $379.9 million in Q3 2024 to a low of -$343.6 million in Q2 2024.
• A 5-year average of $40.1 million and a median of $15.4 million in 2021 frame the typical range for Net Equity Issued and Repurchased.
• Peak annual rise in Net Equity Issued and Repurchased reached 152687.95% in 2024, while the deepest fall reached 182.77% in 2024.
• Tracing IDYA's Net Equity Issued and Repurchased over 5 years: stood at $28.7 million in 2021, then tumbled by 101.31% to -$375000.0 in 2022, then surged by 34119.73% to $127.6 million in 2023, then sank by 182.77% to -$105.6 million in 2024, then soared by 123.68% to $25.0 million in 2025.
• Business Quant data shows IDYA's Net Equity Issued and Repurchased at $25.0 million in Q1 2025, -$105.6 million in Q4 2024, and $379.9 million in Q3 2024.